Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2010 Jun;67(6):750-2.
doi: 10.1001/archneurol.2010.94.

Tarenflurbil: mechanisms and myths

Mary Sano  1
Affiliations
Comment

Tarenflurbil: mechanisms and myths

Mary Sano. Arch Neurol. 2010 Jun.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Green RC, Schneider LS, Amato DA, et al. Tarenflurbil Phase 3 Study Group. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease. JAMA. 2009;302(23):2557–2564. - PMC - PubMed
    1. Wilcock GK, Black SE, Hendrix SB, Zavitz KH, Swabb EA, Laughlin MA Tarenflurbil Phase II Study Investigators. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer’s disease: a randomised phase II trial. Lancet Neurol. 2008;7(6):483–493. - PubMed
    1. Eriksen JL, Sagi SA, Smith TE, et al. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest. 2003;112(3):440–449. - PMC - PubMed
    1. Galasko DR, Graff-Radford N, May S, et al. Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals. Alzheimer Dis Assoc Disord. 2007;21(4):292–299. - PubMed
    1. Martone RL, Zhou H, Atchison K, et al. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer’s disease. J Pharmacol Exp Ther. 2009;331(2):598–608. - PubMed

Publication types